Pioneering technologies that create novel antibody therapeutics to treat cancer and other serious diseases.
Research
Innovation
Discover how ÐǺ£ÆåÅÆ makes a positive impact for patients, communities, employees and the environment
Corporate and financial resources for ÐǺ£ÆåÅÆ investors, potential shareholders and analysts
Resources
Financials
Stock Information
Governance
Our Science
Antibody Technology Platforms
Inspired by nature, our platforms are the foundation for novel therapeutics with the aim of transforming how cancer and other serious diseases are treated.
Our technology platforms harness the power of the human immune system. DuoBody®, HexaBody®, DuoHexaBody® and HexElect® build on natural antibody biology to transform how serious diseases are treated. With these next-generation technologies, we’re taking antibody therapeutics to the next level, with the goal of developing new and transformative treatments.
DuoBody® is an innovative platform for discovering and developing bispecific antibodies, also called dual-targeting molecules. The DuoBody technology platform is capable of generating bispecific antibodies which are dual targeting agents, leading to a variety of effects, including simultaneous recruitment of immune cells and tumor cell recognition.
The HexaBody® platform enables the creation of potent therapeutics. It induces the formation of antibody hexamers (clusters of six) after target binding at the cell surface. This can help to create potent, cytotoxic antibodies and be used to trigger receptors that induce programmed cell death.
DuoHexaBody® combines the dual targeting of ÐǺ£ÆåÅÆ’s DuoBody®  technology with the enhanced potency of HexaBody®. This creates bispecific antibodies that are also able to form antibody-target clusters required for antibody functionality.
HexElect® is a combination of two HexaBody® molecules designed to work together. By selectively targeting cells that express targets for both antibodies, the aim is to maximize treatment potency while minimizing potential toxicity.
With our acquisition of ProfoundBio we have inherited proprietary antibody-drug linker technology, that blends innovative and proven methods to design antibody drug conjugates (ADC) leading to potentially enhanced therapeutic outcomes. ADCs are antibodies with potent cytotoxic agents coupled to them. By using antibodies that recognize specific targets on tumor cells, these cytotoxic agents are preferentially delivered to the tumor cells. We also use or license several other technologies to generate diverse libraries of high quality, functional antibodies such as the UltiMab® transgenic mouse technology from Medarex, Inc., a wholly owned subsidiary of Bristol Myers Squibb, and the OmniAb® transgenic mouse and rat platforms from Ligand Pharmaceuticals, Inc.
